NeoPharm reaches agreement with FDA on phase III "Precise" trial

March 2004
PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20
Market Research Report
Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma multiforme (GBM). Description of GBM as a brain cancer which have limited treatment options; Mission of the clinical trial.


Related Articles

  • Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme. Ung, Nolan; Yang, Isaac // Journal of Neuro-Oncology;Jul2015, Vol. 123 Issue 3, p473 

    Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new...

  • Use of genetically engineered stem cells for glioma therapy (Review). HIROKI NAMBA; HIROSHI KAWAJI; TOMOHIRO YAMASAKI // Oncology Letters;Jan2016, Vol. 11 Issue 1, p9 

    Glioblastoma, the most common and most malignant type of primary brain tumor, is associated with poor prognosis, even when treated using combined therapies, including surgery followed by concomitant radiotherapy with temozolomide-based chemotherapy. The invasive nature of this type of tumor is a...

  • The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. Atif, Fahim; Patel, Neil R.; Yousuf, Seema; Stein, Donald G. // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Glioblastoma multiforme (GBM) is the most common and most aggressive malignant brain tumor. Despite optimal treatment and evolving standard of care, the median survival of patients diagnosed with GBM is only 12–15 months. In this study, we combined progesterone (PROG) and temozolomide...

  • A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC). Chamberlain, Marc; Grimm, Sean; Phuphanich, Surasak; Recht, Larry; Zhu, Jay; Kim, Lyndon; Rosenfeld, Steve; Fadul, Camilo // Journal of Neuro-Oncology;Jun2014, Vol. 118 Issue 2, p335 

    Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary...

  • Current challenges in designing GBM trials for immunotherapy. Weathers, Shiao-Pei; Gilbert, Mark // Journal of Neuro-Oncology;Jul2015, Vol. 123 Issue 3, p331 

    Immune system modulation is evolving into a promising treatment modality in glioblastoma. Our growing understanding of glioma immunobiology has fueled efforts to develop immunotherapeutic strategies to combat this lethal primary brain tumor. Autologous stimulated lymphocytes, immunotherapy with...

  • FDA Wants Another Phase III For NeoPharm's GBM Drug. Morrison, Trista // BioWorld Today;3/30/2007, Vol. 18 Issue 62, p2 

    The author reports on the demand by the U.S. Food and Drug Administration (FDA) Office of Oncology for another phase III trial of cintredekin besudotox, before granting approval for its use in the treatment of recurrent glioblastoma multiforme. The drug failed to meet its primary endpoint in a...

  • Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines. Bhave, Sandeep R.; Dadey, David Y. A.; Karvas, Rowan M.; Ferraro, Daniel J.; Kotipatruni, Rama P.; Jaboin, Jerry J.; Hallahan, Andrew N.; DeWees, Todd A.; Linkous, Amanda G.; Hallahan, Dennis E.; Thotala, Dinesh // Frontiers in Oncology;Sep2013, Vol. 3, p1 

    Purpose: Glioblastoma multiforme (GBM) is an aggressive primary brain tumor that is radio-resistant and recurs despite aggressive surgery, chemo, and radiotherapy. Autotaxin (ATX) is over expressed in various cancers including GBM and is implicated in tumor progression, invasion, and...

  • Orphan drugs in glioblastoma multiforme: a review. Lassen, Ulrik; Mau-S⊘rensen, Morten; Poulsen, Hans Skovgaard // Orphan Drugs: Research & Reviews;2014, Vol. 4, p83 

    Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults. The incidence of GBM in the USA and Europe is 2-3 per 100,000. By definition, an orphan disease affects up to 200,000 persons in the USA (one in every 1,500). A search was made in the US Food and Drug...

  • EOPHARM BEGINS TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA.  // Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p4 

    Highlights progress on the clinical development program of NeoPharm Inc. for IL13-PE38, a novel tumor-targeted agent.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics